Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LIPE | Q05469 | 3/20 | 0.41 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.40 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.40 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.40 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114363 | 0.95 | PPARG (0.48) | PPARGTSHRSMN1; SMN2LIPEPLAAT3 | |
| SCHEMBL5119969 | 0.91 | PPARG (0.48) | PPARGTSHRSMN1; SMN2LIPEPLAAT3 | |
| SCHEMBL5120123 | 0.91 | TSHR (0.47) | PPARGTSHRSMN1; SMN2LIPEPLAAT3 | |
| SCHEMBL5107207 | 0.89 | TSHR (0.46) | PPARGTSHRSMN1; SMN2LIPEPLAAT3 | |
| SCHEMBL5105960 | 0.89 | TSHR (0.48) | PPARGTSHRSMN1; SMN2LIPEPLAAT3 | |
| SCHEMBL5109804 | 0.88 | PPARG (0.57) | PPARGSMN1; SMN2LMNA | |
| SCHEMBL5106647 | 0.88 | TSHR (0.48) | PPARGTSHRSMN1; SMN2LIPEPLAAT3 | |
| SCHEMBL5119471 | 0.81 | MAPK1 (0.50) | LIPEPLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL5113771 | 0.81 | PPARG (0.59) | PPARGTSHRSMN1; SMN2LIPELMNA | |
| SCHEMBL5113011 | 0.80 | PPARG (0.44) | PPARGLIPEPLAAT3PLAAT5PLAAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARG 52/4885TSHR 98/4885SMN1; SMN2 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.